SyntheticMR announced today that their quantitative imaging software solution SyMRI has received regulatory clearance in the UK. It can now be sold and distributed in this market.

"It's very exciting to see our company's continued growth. This regulatory clearance is one step closer to making SyMRI available all over the globe." says Kyle Frye, CCO of SyntheticMR. "We look forward to bringing SyMRI to the UK market and to show how it can transform the clinical workflow in this region and become the standard of care." 

SyMRI NEURO is a quantitative imaging software solution that measures the absolute tissue properties of the brain. SyMRI NEURO provides automatic segmentation of tissue such as myelin volumes, quantification of white matter, gray matter, cerebrospinal fluid and brain parenchymal volume. It is designed to help save valuable time by reducing scan time, all the while aiding as an objective decision support for diagnosis and patient follow-ups.  
 
SyMRI MSK produces quantitative T1, T2, and PD maps and a series of contrast-weighted images in a single fast scan, for both clinical use and advanced research. SyMRI MSK also makes it possible to change echo time (TE), repetition time (TR), and inversion delay (TI) post-scan.  
 

 

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com or Kyle Frye, CCO, SyntheticMR  at +1 (859) 512-9496 or kyle.frye@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.

https://news.cision.com/syntheticmr-ab/r/syntheticmr-s-receives-regulatory-clearance-for-symri-in-the-uk,c3726330

https://mb.cision.com/Main/11663/3726330/1886961.pdf

(c) 2023 Cision. All rights reserved., source Press Releases - English